Pathogens resistant to antimicrobial agents: Epidemiology, molecular mechanisms, and clinical management

Infectious Disease Clinics of North America

Volumn 14, Issue 2, 2000, Pages 293-319

  Kaye, Keith S ^a,b   Fraimow, Henry S ^c,d   Abrutyn, Elias ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c GRADUATE HOSPITAL   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; GLYCOPEPTIDE; MACROLIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0034108512     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70249-X     Document Type: Article

References (177)

1. C. Amabile-Cuevas Origins, Evolution and Spread of Antibiotic Resistance Genes 1993 RG Landes Austin, TX 24 67
2. V.T. Andriole The Quinolones 1998 Academic Press New York
3. G.L. Archer D.M. Niemeyer J.A. Thanassi Dissemination among staphylococci of DNA sequences associated with methicillin resistance Antimicrob Agents Chemother 38 1994 447 454
4. M. Arthur P. Courvalin Genetics and mechanisms of glycopeptide resistance in enterococci Antimicrob Agents Chemother 37 1993 1563 1571
5. F. Asensi M.C. Otero D. Perez-Tamarit Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus J Chemother 5 1993 133 134
6. J.G. Bartlett R.F. Breiman L.A. Mandell Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America Clin Infect Dis 26 1998 811 838
7. F. Biavasco C. Vignaroli R. Lupidi In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide Antimicrob Agents Chemother 41 1997 2165 2172
8. J. Blahova M. Lesicka-Hupkova K. Kralikova Further occurrence of extended-spectrum beta-lactamase-producing Salmonella enteritidis J Chemother 10 1998 294 291
9. J.M. Boyce S.M. Opal G. Potter-Bynoe Emergence and nosocomial transmission of ampicillin-resistant enterococci Antimicrob Agents Chemother 36 1992 1032 1039
10. R.F. Breiman J.C. Butler F.C. Tenover Emergence of drug-resistant pneumococcal infections in the United States JAMA 271 1994 1831 1835
11. D.R. Burwen S.N. Banerjee R.P. Gaynes Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System J Infect Dis 170 1994 1622 1625
12. L.M. Bush J. Calmon C.L. Cherney High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections Ann Intern Med 110 1989 515 520
13. Campbell G.D. Jr R. Silberman Drug-resistant Streptococcus pneumoniae Clin Infect Dis 26 1998 1195 1188
14. CDC Assessment of Testing for and Completeness of Reporting of Vancomycin-Resistant Enterococci-Connecticut, 1994 MMWR 45 1996 289 291
15. CDC Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin MMWR 46 1997 626
16. CDC Nosocomial enterococci resistant to vancomycin-United States, 1989–1993 MMWR 42 1993 597 599
17. CDC Preventing the spread of vancomycin resistance-report from the hospital infection control practices advisory committee Federal Register 59 1994 25757 25763
18. CDC Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 46 1997 1 24
19. CDC Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) MMWR 44 1995 1 13
20. CDC Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997 MMWR 46 1997 765 766
21. E.B. Chaibi D. Sirot G. Paul Inhibitor-resistant TEM beta-lactamases: Phenotypic, genetic and biochemical characteristics J Antimicrob Chemother 43 1999 447 458
22. H.F. Chambers Detection of methicillin-resistant staphylococci Infect Dis Clin North Am 7 1993 425 433
23. J.W. Chow S.M. Donahedian M.J. Zervos Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia Clin Infect Dis 24 1997 90 91
24. J.W. Chow M.J. Fine D.M. Shlaes Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy Ann Intern Med 115 1991 585 590
25. M.W. Climo R.L. Patron G.L. Archer Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin [in process citation] Antimicrob Agents Chemother 43 1999 1747 1753
26. M.A. Cohen M.D. Huband J.W. Gage In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin J Antimicrob Chemother 40 1997 205 211
27. P.E. Coudron E.S. Moland C.C. Sanders Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: Seek and you may find J Clin Microbiol 35 1997 2593 2597
28. P. Courvalin Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria Antimicrob Agents Chemother 38 1994 1447 1451
29. K. Crossley D. Loesch B. Landesman An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies J Infect Dis 139 1979 273 279
30. W. Cullmann Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates Chemotherapy 37 1991 246 250
31. E. D'Agata L. Venkataraman P. DeGirolami The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital J Infect 36 1998 279 285
32. T.E. Daum D.R. Schaberg M.S. Terpenning Increasing resistance of Staphylococcus aureus to ciprofloxacin Antimicrob Agents Chemother 34 1990 1862 1863
33. J. Davies Inactivation of antibiotics and the dissemination of resistance genes Science 264 1994 375 382
34. De Champs C. D. Rouby D. Guelon A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase J Hosp Infect 18 1991 5 13
35. M. Denton K.G. Kerr Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia Clin Microbiol Rev 11 1998 80 57
36. G.V. Doern M.A. Pfaller M.E. Erwin The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada—1997 results from the SENTRY Antimicrobial Surveillance Program Diagn Microbiol Infect Dis 32 1998 313 316
37. G.V. Doern M.A. Pfaller K. Kugler Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program Clin Infect Dis 27 1998 764 770
38. S.F. Dowell J.C. Butler G.S. Giebink Acute otitis media: Management and surveillance in an era of pneumococcal resistance—a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group Pediatr Infect Dis J 18 1999 1 9
39. M. Dowzicky H.L. Nadler C. Feger Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates Am J Med 104 1998 34S 42S
40. R.J. Dworkin B.L. Lee M.A. Sande Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin Lancet 2 1989 1071 1073
41. M.B. Edmond J.F. Ober D.L. Weinbaum Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection [see comments] Clin Infect Dis 20 1995 1126 1133
42. G.M. Eliopoulos Aminoglycoside resistant enterococcal endocarditis Infect Dis Clin North Am 7 1993 117 133
43. G.M. Eliopoulos Vancomycin-resistant enterococci. Mechanism and clinical relevance Infect Dis Clin North Am 11 1997 851 865
44. C.L. Emery L.A. Weymouth Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center J Clin Microbiol 35 1997 2061 2067
45. F. Fitoussi C. Doit K. Benali Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis Antimicrob Agents Chemother 42 1998 942 944
46. C.W. Ford J.C. Hamel D.M. Wilson In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections Antimicrob Agents Chemother 40 1996 1508 1513
47. D.H. Forster F.D. Daschner Acinetobacter species as nosocomial pathogens [editorial] Eur J Clin Microbiol Infect Dis 17 1998 73 77
48. H.S. Fraimow E. Venuti Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium Antimicrob Agents Chemother 36 1992 1566 1563
49. S.K. Fridkin S.F. Welbel R.A. Weinstein Magnitude and prevention of nosocomial infections in the intensive care unit Infect Dis Clin North Am 11 1997 479 496
50. I.R. Friedland K.P. Klugman Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis Lancet 339 1992 405 408
51. Friedland I.R. McCracken G.H. Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae N Engl J Med 331 1994 382 377
52. I.R. Friedland M. Paris S. Ehrett Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis Antimicrob Agents Chemother 37 1993 1630 1636
53. Garcia-Rodriguez J.A. Garcia Sanchez J.E. Munoz Bellido J.L. Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia J Antimicrob Chemother 27 1991 554 552
54. M.L. Grayson G.M. Eliopoulos C.B. Wennersten Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: A 22-year review at one institution Antimicrob Agents Chemother 35 1991 2180 2184
55. R. Hakenbeck T. Briese L. Chalkley Antigenic variation of penicillin-binding proteins from penicillin-resistant clinical strains of Streptococcus pneumoniae J Infect Dis 164 1991 319 313
56. S. Handwerger B. Raucher D. Altarac Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin Clin Infect Dis 16 1993 750 755
57. M.K. Hayden G.M. Trenholme J.E. Schultz In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate J Infect Dis 167 1993 1224 1227
58. B.C. Herold L.C. Immergluck M.C. Maranan Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk [see comments] JAMA 279 1998 593 598
59. K. Hiramatsu N. Aritaka H. Hanaki Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin Lancet 350 1997 1670 1673
60. K. Hiramatsu H. Hanaki T. Ino Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 1997 135 136
61. J.A. Hoogkamp-Korstanje In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections J Antimicrob Chemother 40 1997 427 431
62. G.S. Itokazu J.P. Quinn C. Bell-Dixon Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: Evaluation of a national postmarketing surveillance program Clin Infect Dis 23 1996 779 784
63. C. Jacobs Pharmacia Biotech & Science prize. 1997 grand prize winner. Life in the balance: Cell walls and antibiotic resistance Science 278 1997 1731 1732
64. C. Jacobs J.M. Frere S. Normark Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria Cell 88 1997 823 832
65. Jacoby G: Amino acid sequences for TEM, SHV and OXA extended-spectrum beta-lactamases. Available at: http://www.lahey.hitchcock.org/pages/1hc/studies/webt.htm. Accessed 1999
66. G.A. Jacoby Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams Infect Dis Clin North Am 11 1997 875 887
67. G.A. Jacoby Genetics of extended-spectrum beta-lactamases Eur J Clin Microbiol Infect Dis 13 1994 S2 11
68. G.A. Jacoby I. Carreras Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases Antimicrob Agents Chemother 34 1990 858 862
69. G.A. Jacoby P. Han Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli J Clin Microbiol 34 1996 911 908
70. A.P. Johnson M. Warner R.C. George Oxacillin-resistant pneumococci sensitive to penicillin Lancet 341 1993 1222
71. R.N. Jones M.A. Pfaller G.V. Doern Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group Diagn Microbiol Infect Dis 30 1998 215 228
72. R.N. Jones M.A. Pfaller S.A. Marshall Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes Diagn Microbiol Infect Dis 29 1997 187 192
73. H. Kapoor P. Aggarwal Resistance to quinolones in pathogens causing urinary tract infections J Commun Dis 29 1997 263 267
74. J.A. Karas D.G. Pillay D. Muckart Treatment failure due to extended spectrum beta-lactamase J Antimicrob Chemother 37 1996 203 204
75. I. Klare H. Heier H. Claus Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community Microb Drug Resist 1 1995 265 272
76. K.P. Klugman Management of antibiotic-resistant pneumococcal infections J Antimicrob Chemother 34 1994 191 193
77. K.P. Klugman Pneumococcal resistance to antibiotics Clin Microbiol Rev 3 1990 171 196
78. D.J. Krogstad T.R. Korfhagen Moellering R.C. Jr Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis: An explanation for resistance to antibiotic synergism J Clin Invest 62 1978 480 486
79. E. Lautenbach M.G. Schuster W.B. Bilker The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus Clin Infect Dis 27 1998 1265 1259
80. M.T. Lawlor M.C. Sullivan R.E. Levitz Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline [letter] J Infect Dis 161 1990 812 814
81. R. Leclercq E. Derlot M. Weber Transferable vancomycin and teicoplanin resistance in Enterococcus faecium Antimicrob Agents Chemother 33 1989 15 10
82. R.J. Leggiadro The clinical impact of resistance in the management of pneumococcal disease Infect Dis Clin North Am 11 1997 867 874
83. O.S. Levine M. Farley L.H. Harrison Risk factors for invasive pneumococcal disease in children: A population-based case-control study in North America Pediatrics 103 1999 E28
84. J. Linares T. Alonso J.L. Perez Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics J Antimicrob Chemother 30 1992 279 288
85. P.K. Linden Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance Am J Med 104 1998 24S 33S
86. D.M. Livermore Acquired carbapenemases J Antimicrob Chemother 39 1997 673 676
87. D.M. Livermore beta-Lactamases in laboratory and clinical resistance Clin Microbiol Rev 8 1995 557 584
88. Livornese L.L. Jr S. Dias C. Samel Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers Ann Intern Med 117 1992 112 116
89. D.E. Low Resistance issues and treatment implications: Pneumococcus, Staphylococcus aureus, and gram-negative rods Infect Dis Clin North Am 12 1998 613 630
90. B.R. Lyon R. Skurray Antimicrobial resistance of Staphylococcus aureus: Genetic basis Microbiol Rev 51 1987 88 134
91. F.M. MacKenzie I.M. Gould Extended spectrum beta-lactamases J Infect 36 1998 255 258
92. G.L. Mandell J.E. Bennett R. Dolin Principles and Practice of Infectious Diseases 1995 Churchill Livingstone New York
93. N. Markowitz E.L. Quinn L.D. Saravolatz Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection Ann Intern Med 117 1992 390 398
94. L. Martinez-Martinez S. Hernandez-Alles S. Alberti In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins Antimicrob Agents Chemother 40 1996 342 348
95. McMurry L. Petrucci R.E. Jr S.B. Levy Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli Proc Natl Acad Sci USA 77 1980 3977 3974
96. A.A. Medeiros Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics Clin Infect Dis 24 suppl 1 1997 S19 S45
97. A.A. Medeiros J. Crellin Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: Effect of large inocula Pediatr Infect Dis J 16 1997 S49 S55
98. K.S. Meyer C. Urban J.A. Eagan Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins Ann Intern Med 119 1993 353 358
99. G.H. Miller F.J. Sabatelli R.S. Hare The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: A reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups Clin Infect Dis 24 suppl 1 1997 S46 S62
100. M.H. Miller S.C. Edberg L.J. Mandel Gentamicin uptake in wild-type and aminoglycoside-resistant small-colony mutants of Staphylococcus aureus Antimicrob Agents Chemother 18 1980 729 722
101. Moellering R.C. Therapeutic options for infections caused by multiply-resistant enterococci Abstracts of the 34th Interscience Conference of Antimicrobial Agents and Chemotherapy 1994 American Society for Microbiology Orlando, FL 292
102. J.Z. Montgomerie Epidemiology of Klebsiella and hospital-associated infections Rev Infect Dis 1 1979 736 753
103. B. Moreira S. Boyle-Vavra deJonge B.L. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus Antimicrob Agents Chemother 41 1997 1793 1788
104. R.R. Muder A.P. Harris S. Muller Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: A prospective, multicenter study of 91 episodes Clin Infect Dis 22 1996 508 512
105. M.E. Mulligan K.A. Murray-Leisure B.S. Ribner Methicillin-resistant Staphylococcus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management Am J Med 94 1993 313 328
106. R. Munoz J.M. Musser M. Crain Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: Characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis Clin Infect Dis 15 1992 112 118
107. K. Murakami A. Tomasz Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus J Bacteriol 171 1989 879 874
108. B.E. Murray Beta-lactamase-producing enterococci Antimicrob Agents Chemother 36 1992 2355 2359
109. B.E. Murray The life and times of the Enterococcus Clin Microbiol Rev 3 1990 65 46
110. B.E. Murray K.V. Singh S.M. Markowitz Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states J Infect Dis 163 1991 780 785
111. S. Nakashio H. Iwasawa F.Y. Dun Everninomicin, a new oligosaccharide antibiotic: Its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity Drugs Exp Clin Res 21 1995 7 16
112. National Nosocomial Infections Surveillance (NNIS) report dsfO-A, issued May 1996: A report from the National Nosocomial Infections Surveillance (NNIS) System Am J Infect Control 24 1996 388 380
113. NCCLS (National Committee for Clinical Laboratory Standards): Performance Standards for Antimicrobial Susceptibility Testing: Ninth Informational Supplement 1999 National Committee for Clinical Laboratory Standards Wayne, PA Document M100-S9
114. H.C. Neu The crisis in antibiotic resistance Science 257 1992 1064 1073
115. H. Nikaido Prevention of drug access to bacterial targets: Permeability barriers and active efflux Science 264 1994 382 388
116. NNIS (National Nosocomial Infections Surveillance): NNIS Semiannual Report 1998 US Department of Health & Human Services Atlanta, GA
117. W.C. Noble Z. Virani R.G. Cree Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus FEMS Microbiol Lett 72 1992 198 195
118. P. Nordmann M. Guibert Extended-spectrum beta-lactamases in Pseudomonas aeruginosa J Antimicrob Chemother 42 1998 131 128
119. A.H. Norris J.P. Reilly P.H. Edelstein Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections Clin Infect Dis 20 1995 1137 1144
120. M. Onorato M.J. Borucki G. Baillargeon Risk factors for colonization or infection due to methicillin-resistant Staphylococcus aureus in HIV-positive patients: A retrospective case-control study Infect Control Hosp Epidemiol 20 1999 26 30
121. R. Pallares F. Gudiol J. Linares Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci N Engl J Med 317 1987 18 22
122. R. Pallares M. Pujol C. Pena Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia. A matched case-control study Arch Intern Med 153 1993 1581 1586
123. B. Pangon C. Bizet A. Bure In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase J Infect Dis 159 1989 1005 1006
124. G.A. Pankuch M.R. Jacobs P.C. Appelbaum Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin Antimicrob Agents Chemother 38 1994 369 370
125. G.A. Pankuch M.A. Visalli M.R. Jacobs Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents Antimicrob Agents Chemother 42 1998 624 630
126. A.L. Panlilio D.H. Culver R.P. Gaynes Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975–1991 Infect Control Hosp Epidemiol 13 1992 582 586
127. G.A. Papanicolaou A.A. Medeiros G.A. Jacoby Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae Antimicrob Agents Chemother 34 1990 2209 2200
128. J.E. Patterson M.J. Zervos High-level gentamicin resistance in Enterococcus: Microbiology, genetic basis, and epidemiology Rev Infect Dis 12 1990 644 652
129. J.C. Pechere I.R. Vladoianu Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model J Antimicrob Chemother 29 1992 563 573
130. C. Pena M. Pujol C. Ardanuy Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases Antimicrob Agents Chemother 42 1998 53 58
131. C. Pena M. Pujol A. Ricart Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit J Hosp Infect 35 1997 9 16
132. B. Perichon P. Reynolds P. Courvalin VanD-type glycopeptide-resistant Enterococcus faecium BM4339 Antimicrob Agents Chemother 41 1997 2016 2018
133. P.J. Petersen N.V. Jacobus W.J. Weiss In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 1999 738 744
134. M.A. Pfaller R.N. Jones G.V. Doern Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the E test method. The Venezuelan Antimicrobial Resistance Study Group Diagn Microbiol Infect Dis 30 1998 45 52
135. L.J. Piddock M. Johnson V. Ricci Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract Antimicrob Agents Chemother 42 1998 2956 2960
136. A. Pikis J.A. Donkersloot S. Akram Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae J Antimicrob Chemother 40 1997 108 105
137. L. Piroth H. Aube J.M. Doise Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: Are beta-lactamase inhibitors of therapeutic value? Clin Infect Dis 27 1998 76 80
138. J.D. Pitout K.S. Thomson N.D. Hanson Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains Antimicrob Agents Chemother 42 1998 596 600
139. J.D. Pitout K.S. Thomson N.D. Hanson beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa Antimicrob Agents Chemother 42 1998 1350 1354
140. M.C. Ploy C. Grelaud C. Martin First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital Lancet 351 1998 1212
141. Quintiliani R. Jr S. Evers P. Courvalin The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci J Infect Dis 167 1993 1220 1223
142. J.J. Rahal C. Urban D. Horn Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella JAMA 280 1998 1237 1233
143. M. Rahman S. Connolly W.C. Noble Diversity of staphylococci exhibiting high-level resistance to mupirocin J Med Microbiol 33 1990 97 100
144. M.R. Reichler A.A. Allphin R.F. Breiman The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio J Infect Dis 166 1992 1346 1353
145. R.R. Reinert M. Kresken V. Mechery In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae Eur J Clin Microbiol Infect Dis 17 1998 665 662
146. L.B. Rice E.C. Eckstein J. DeVente Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center Clin Infect Dis 23 1996 118 124
147. K.V. Rolston D.H. Ho B. LeBlanc In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer J Antimicrob Chemother 39 Suppl B 1997 15 22
148. M.J. Rybak D.M. Cappelletty T. Moldovan Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium Antimicrob Agents Chemother 42 1998 724 721
149. C.C. Sanders beta-Lactamases of gram-negative bacteria: New challenges for new drugs Clin Infect Dis 14 1992 1089 1099
150. C.C. Sanders Cefepime: The next generation? Clin Infect Dis 17 1993 369 379
151. C.C. Sanders A.L. Barry J.A. Washington Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test J Clin Microbiol 34 1996 2997 3001
152. Sanders W.E. Jr C.C. Sanders Inducible beta-lactamases: Clinical and epidemiologic implications for use of newer cephalosporins Rev Infect Dis 10 1988 830 838
153. D.A. Schiappa M.K. Hayden M.G. Matushek Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation J Infect Dis 174 1996 529 536
154. H. Seifert A. Strate G. Pulverer Nosocomial bacteremia due to Acinetobacter baumannii: Clinical features, epidemiology, and predictors of mortality Medicine (Baltimore) 74 1995 349 340
155. K.J. Shaw P.N. Rather R.S. Hare Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes Microbiol Rev 57 1993 138 163
156. D.M. Shlaes L. Etter L. Gutmann Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin Antimicrob Agents Chemother 35 1991 776 779
157. K. Sieradzki R.B. Roberts S.W. Haber The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection [see comments] N Engl J Med 340 1999 517 523
158. K. Sieradzki A. Tomasz Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis Microb Drug Resist 4 1998 159 168
159. D.L. Sirot F.W. Goldstein C.J. Soussy Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: A 3-year survey in France Antimicrob Agents Chemother 36 1992 1677 1681
160. P.M. Small H.F. Chambers Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users Antimicrob Agents Chemother 34 1990 1227 1231
161. A.M. Smith K.P. Klugman T.J. Coffey Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa Antimicrob Agents Chemother 37 1993 1938 1944
162. S.M. Smith A. Mangia R.H. Eng Clindamycin for colonization and infection by methicillin-resistant Staphylococcus aureus Infection 16 1988 97 95
163. T.L. Smith M.L. Pearson K.R. Wilcox Emergence of vancomycin resistance in Staphylococcus aureus: Glycopeptide-Intermediate Staphylococcus aureus Working Group [see comments] N Engl J Med 340 1999 493 501
164. S. Soares K.G. Kristinsson J.M. Musser Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s J Infect Dis 168 1993 158 163
165. Spargo J. Enhanced detection of extended-spectrum beta-lactamases by the Vitek ESBL test Programs and Abstracts of the 38th Interscience Conference of Antimicrobial Agents and Chemotherapy 1998 American Society for Microbiology San Diego, CA 141
166. B.G. Spratt Resistance to antibiotics mediated by target alterations Science 264 1994 388 393
167. F.C. Tenover M.V. Lancaster B.C. Hill Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides J Clin Microbiol 36 1998 1020 1027
168. A. Tomasz Antibiotic resistance in Streptococcus pneumoniae Clin Infect Dis 24 suppl 1 1997 S85 S88
169. N.G. Tornieporth R.B. Roberts J. John Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients Clin Infect Dis 23 1996 767 772
170. C. Torres J.A. Reguera M.J. Sanmartin vanA-mediated vancomycin-resistant Enterococcus spp. in sewage J Antimicrob Chemother 33 1994 553 561
171. C. Urban N. Mariano K. Mosinka-Snipas Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin J Antimicrob Chemother 37 1996 361 364
172. S. Vartivarian E. Anaissie G. Bodey A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: Implications for therapy Antimicrob Agents Chemother 38 1994 624 627
173. J. Vila J. Ruiz P. Goni Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii J Antimicrob Chemother 39 1997 757 762
174. P.F. Viladrich F. Gudiol J. Linares Evaluation of vancomycin for therapy of adult pneumococcal meningitis Antimicrob Agents Chemother 35 1991 2467 2472
175. J. Wiener J.P. Quinn P.A. Bradford Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes JAMA 281 1999 517 523
176. Williamson R. le Bouguenec C. L. Gutmann One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin J Gen Microbiol 131 1985 1933 1940
177. W. Zimmerli A.F. Widmer M. Blatter Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group JAMA 279 1998 1537 1541